https://scholars.lib.ntu.edu.tw/handle/123456789/635377
標題: | Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells | 作者: | SHANG-JU WU Lin, Chien-Ting Liao, Cheng Hao Lin, Chun-Ming |
關鍵字: | Bispecific antibody; Blinatumomab; CD19-targeting; γ9δ2 T cells | 公開日期: | 五月-2023 | 卷: | 31 | 起(迄)頁: | 101650 | 來源出版物: | Translational oncology | 摘要: | Previous studies have explored the use of engineered blinatumomab-secreting autologous αβ T cells for CD19-targeted cancer therapy. To create a more flexible allogeneic delivery system, we utilized γ9δ2 T cells rather than αβ T cells in a similar application. First, we showed that γ9δ2 T cells could serve as effector cells for blinatumomab, and these effector memory cells could survive for at least 7 days after infusion. The genetically modified blinatumomab-secreting γ9δ2 T cells induced significant cytotoxicity in CD19+ tumor cell lines and primary cells from chronic lymphocytic leukemia patients. Of note, blinatumomab-secreting γ9δ2 T cells might also exhibit dual-targeting of CD19 and isopentenyl pyrophosphate, a universal tumor-associated antigen. Furthermore, blinatumomab-secreting γ9δ2 T cells killed CD19-transfected adherent cells, suggesting that the γ9δ2 T cells might be effective for treating solid tumors with appropriate cancer antigens. Together, these results demonstrate the promise of blinatumomab-secreting γ9δ2 T cells as a cancer therapy. |
URI: | https://www.scopus.com/record/display.uri?eid=2-s2.0-85149748638&doi=10.1016%2fj.tranon.2023.101650&origin=inward&txGid=d8e0cff7db05d68479151e3f999d4b9b https://scholars.lib.ntu.edu.tw/handle/123456789/635377 |
ISSN: | 1936-5233 | DOI: | 10.1016/j.tranon.2023.101650 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。